Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions

It is now well established that clinically stable patients with relapsing–remitting multiple sclerosis have ongoing disease activity when evaluated by serial gadolinium–enhanced (Gd‐DTPA) magnetic resonance imaging (MRI) scans. Despite this, the relationship between clinical disease and MRI lesions, though suspected, has not been extensively documented. The relationship between Gd‐DTPA MRI lesions, and clinical disease was examined in this study of 9 patients with mild relapsing–remitting multiple sclerosis (Expanded Disability Status Scale [EDSS] <3.5) who had 24 to 37 monthly Gd‐DTPA MRI scans, neurological examinations, and EDSS score assignments. The area and frequency of Gd‐DTPA lesions were examined during months with and without clinical worsening as measured by EDSS. Forty‐one episodes of clinical worsening were noted during the study. A significant association was observed between these periods of clinical worsening and MRI parameters, including increases in total number, number of new lesions, and the total area of enhancement. Logistic regression analysis showed a signficant effect of the number and area of Gd‐DTPA MRI lesions on both the onset and continuation of clinical worsening, confirming an imporant relationship between clinical disease and an increase in cerebral Gd‐DTPA MRI activity. A relationship with long‐term disability was suggested, but cannot be confirmed without longer follow‐up of these patients.

[1]  A. Thompson,et al.  Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration , 1992, Neurology.

[2]  D. McFarlin,et al.  Multiple sclerosis (first of two parts). , 1982, New England Journal of Medicine.

[3]  L Bozzao,et al.  SPECT, MRI and cognitive functions in multiple sclerosis. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[4]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[5]  J. Oger,et al.  Multiple sclerosis , 1988, Neurology.

[6]  P. Scheltens,et al.  Quantitative MRI changes in gadolinium‐DTPA enhancement after high‐dose intravenous methylprednisolone in multiple sclerosis , 1991, Neurology.

[7]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[8]  V. Haughton,et al.  Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis , 1989, Neurology.

[9]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[10]  F. Barkhof,et al.  Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. , 1992, AJR. American journal of roentgenology.

[11]  B E Kendall,et al.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.

[12]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[13]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[14]  D. Thomas,et al.  A Gibbs sampling approach to linkage analysis. , 1992, Human heredity.

[15]  A. Thompson,et al.  High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[16]  W. I. McDonald,et al.  Heterogeneity of blood‐brain barrier changes in multiple sclerosis , 1990, Neurology.

[17]  R. Murray,et al.  The effect of high‐dose steroids on MRI gadolinium enhancement in acute demyelinating lesions , 1991, Neurology.

[18]  D. McFarlin,et al.  Multiple sclerosis (second of two parts). , 1982, The New England journal of medicine.

[19]  F. Barkhof,et al.  A correlative triad of gadolinium‐DTPA MRI, EDSS, and CSF‐MBP in relapsing multiple sclerosis patients treated with high‐dose intravenous methylprednisolone , 1992, Neurology.

[20]  N. Patronas,et al.  Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.

[21]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[22]  C. Pozzilli,et al.  Serial study of gadolinium‐DTPA MRI enhancement in multiple sclerosis , 1990, Neurology.

[23]  S W Atlas,et al.  Multiple sclerosis: gadolinium enhancement in MR imaging. , 1986, Radiology.

[24]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[25]  B E Kendall,et al.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.

[26]  R. Capra,et al.  Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. , 1992, Archives of neurology.